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ABSTRACT 
Introduction 
Collection, processing and distribution of safe blood in Tanzania occurs within a 
free-for-service context, that is, a collection from non-remunerated blood 
donors and distributing freely to the needy people through health facilities. 
The safe blood services in the country appear to be crippled with many 
challenges and cannot meet the demand for blood and its products.  As such, a 
need for rethinking collection methods, financial models and possible 
mechanisms for donor remuneration is evident.  
 
Methods 
In this paper, we venture on multi-stakeholder meetings and ongoing 
discussions regarding the internal mechanisms of safe blood transfusion 
financing.  The intent is to offer a perspective on the considerations for self-
sustaining safe blood services in the country and the extent to which they may 
be implemented or not.  
 
Results 
We suggest that despite huge demand, the external donor dependent 
financing mechanisms for safe blood services in the country are ineffective. 
Therefore, we discuss two potential ‘internal’ financing mechanisms that have 
been identified in recent shareholders forums 1) introducing a blood processing 
fee accompanied by policy change to allow direct charging of either recipients 
or hospitals or 2) influencing the introduction of ‘blood services’ within the 
current insurance schemes. 
 
Conclusion 
We conclude that there is a need for constructing alternative financial mechanisms to sustain the demand of 
safe blood in the country. We discuss two cost recovery mechanisms, blood processing fee and insurance 
schemes; however, warning is noted that their implementation warrants structural adjustments, massive 
community sensitization and optimum stakeholder engagement to maximize acceptability within the 
country.  
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INTRODUCTION 
Safe blood supply is an important facet of health care 
services in any country.  The benefits of safe blood 
services extend beyond saving lives of millions of 
mothers and others in need of blood products to the 
reduction in transfusion-transmissible infections such 
as HIV,  Hepatitis B and C Viruses and syphilis among 
blood recipients.1 – 6  For example, between 2004 and 
2012, safe blood services was considered to 
contribute in reducing prevalence of transfusion 
related  HIV from 7-percent to 1-percent, syphilis and 
Hepatitis C stands at less than 1-percent in Tanzania.6 
It is for these reasons that a need for sustainable 
blood supply is indispensable.   
 
Safe blood supply in Tanzania envisages three steps 
which are; collection of blood from voluntary non-
enumerated donors, processing and distribution to 
hospitals who then transfuse all patients in need.6 - 8 
The National Blood Transfusion Services (NBTS), an 
entity which deals with regulating, collection, 
processing and distribution of safe blood in the 
country 7 has  continued to embrace donor and public 
funding of services “to ensure easily accessible and 
adequate supply of safe and high quality blood….to  
all  who  need  it  irrespective  of  their  economic  or  
social  status.” The entity, therefore handles the 
training of staff, blood collection, storage and 
transportation activities within the country. 
Furthermore, the agency is expected to provide 
guidance to all actors for the betterment of blood 
transfusion practices and ensure harmony and the 
use of standardized guidelines across institutions.7 
While the agency has continued to achieve its 
administrative roles; challenges in financing safe 
blood in the country persist.   
 
There is unmatched funding in comparison to the 
persistently increasing demand for safe blood in the 
country. NBTS reports indicate that donor funds 
decreased from 72-percent of total funds in 2006 to 
49-percent in 2011.6,9 Interestingly, the annual 
demand for blood in 2013 was estimated to exceed 
450,000 units per year, which required $10,752,000, 
with NBTS only able to meet 30-percent of the 
need.6, 8, 9 This unfavorable trend has sparked off a 
discussion among stakeholders for diversifying 
financial resources. The decrease in ‘external’ funds 
has propelled the stakeholders to eye on financial 
mechanisms from the ‘internal’ sources. As such, 
there have been efforts to advocate for diversified 
cost recovery mechanisms, particularly from the 
direct beneficiaries of blood transfusion.8 In this 
article, we present the potential internal sources that 
have been a hallmark of stakeholder discussions and 
key issues to consider in their implementation within 
the country. 
 
METHODS 
This paper is descriptive in nature, venturing on the 
proceedings of the multi-stakeholders’ task force in 
Tanzania between 2014 and 2015 and the ongoing 
discussions afterwards. The goal of this task force 
was to review the current blood financing 
mechanisms in Tanzania and to guide the agency in 
discerning a way forward. The group, comprising of 
NBTS staffs, stakeholders and experts met three 
times within a year and brainstormed about potential 
internal financial mechanisms for blood services. 
Since then, the discussion on the topic is ongoing.  
 
RESULTS 
The group acknowledged that there is a huge 
demand for blood products within the country, 
however, the external donor dependent financing 
mechanisms for safe blood services are inadequate 
and unsustainable. The NBTS was established 
through an agreement between donor government 
and the Tanzania Government in 2004 in line with the 
World Health Assembly Resolution WHA 28.72 
(1972); which urges all member states to develop 
comprehensive and well-coordinated blood 
transfusion services based on voluntary, non-
remunerated blood donors.7 Since its establishment, 
the agency has mainly depended on external donors 
which has been greatly inconsistent with donors 
‘tapering’ their funds (Table 1). As such, there is a 
need to consider internal sources for financing safe   
blood transfusion services to ensure sustainability.  
 
The decreased funding means that Tanzania is 
unable to meet the blood transfusion services cost. 
For example, the NBTS suggests that the operating 
cost of suitable and safe blood in the country is about 
$ 76.8 per unit in Tanzania entailing the cost incurred 
in the recruitment, collection, screening, testing, 
production, distribution and health education.9 
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However, the estimated annual demand for safe 
blood appears to exceed the agency supply 
capacity.6,8,9  
 
 
Table 1 Financing Trend for NBTS, 2006 – 2011   
Year Amount  
required 
(USD) 
Amount received  
from  MOHSW 
(USD) 
Amount received from 
CDC and other donors 
(USD) 
Total amount 
received (USD) 
Variance 
(USD) 
2006 5,500,000 0 3,945,885(72%) 3,954,885(72%) 1,554,115(28%) 
2009 6,200,000 270,000(4%) 3,900,000(63%) 4,170,000(67%) 2,030,000(33%) 
2010 6,300,000 560,000(9%) 4,000,000(64%) 4,560,000(72%) 1,740,000(28%) 
2011 6,400,000 177,000(3%) 3,150,000(49%) 3,327,000(52%) 3,073,000(48%) 
Source: National Blood Transfusion Services 6,9 
 
DISCUSSION 
Given the insufficiency of external financial donations 
(Table 1), the huge financial requirements for 
collection, processing and distribution; and 
inadequate cost recovery mechanisms, the country 
lacks the capacity to meet the demand. Therefore, 
the group unmasked two potential ‘internal’ blood 
financing mechanisms. Firstly, the introduction of 
blood processing fee and subsequent policy changes 
and influencing the introduction of ‘blood services’ 
within the current insurance schemes. 
 
The introduction of blood processing fee as a way of 
cost recovery through direct charging blood 
recipients in terms of user fees or hospitals is 
consistent with Gerald and colleagues10  who suggest 
that cost recovery mechanisms can be done by 
1.Spreading the cost of blood across user fees paid 
by all inpatients  
2. Charging the recipient of blood directly and  
3. Charging hospitals directly for blood used.   
 
While we propose the introduction of blood 
processing fee in the country, we understand that 
this approach is not without its challenges. To start 
with, the NBTS’s focus and mission may need to 
undergo some changes. The agency’s mission 
categorizes blood and its products as ‘a public good’ 
because it is collected from voluntary, non-
remunerated blood donors.6,9 Voluntary, non-
remunerated donation is promoted by the World 
Health Organization.1, 11  Boyle and colleagues 12 also 
concur with WHO as their report indicates  lower risk 
of HIV transmission in volunteer donors than paid or 
family donors. Since blood is obtained ‘free’ making 
it a public good, charging for it will necessitate 
changing the agency’s mission and their strategic 
approaches.  
 
Additionally, there are ethical concerns to consider 
regarding safe blood services and the charging of 
patients.  Ethically, charging an individual patient 
may not be justifiable due to the fact that blood is 
not only freely donated but is also transfused to 
clinically ill patients, carefully selected and those in 
need for it.13 Furthermore, most of the blood 
recipients are mainly under-five children and 
pregnant women who are exempted under the 
current health service structure.6, 8, 9, 14  Embracing 
the fee exemption to this group will inevitably 
reduce the possible revenue base significantly. As 
such, policy change or charging the hospital may be 
a necessity. Lastly, is the practicability of introducing 
user fees in the country at a time when the political 
environment is fragile. We revisited the experiences 
of Malawi and other countries and noted that in 
many countries, only a limited portion of the cost of 
providing safe blood can realistically be raised from 
users. Therefore, cost recovery from user fees even 
in policy change, maybe challenging to implement in 
the country.  
 
We therefore suggest that, if NBTS were to conceive 
the user fee as an option, any attempt to implement 
the proposed strategies in the country would require 
the following 
1.Large-scale policy change to create friendly 
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political and social environment for charging for 
blood,  
2.Seeking approval from the ‘public’ who are 
‘volunteers’ and ‘not remunerated’ for the ‘products’ 
they donate  
3.Intra-country advocacy for treating blood as an 
essential product.  
 
After a long debate and global advocacy2,3 the recent 
WHO essential medicine list appears to include 
fresh–frozen plasma, platelets, red blood cells and 
whole blood as essential medicines.11  As an essential 
medicine, the agency may then need to charge user 
fees or hospitals and allow users or hospitals to 
purchase blood from the agency directly. However, a 
massive advocacy campaign within the country 
might be integral in changing   the pro-public 
ideologies of not only the political system, but also 
the health facilities and citizens towards blood 
transfusion services in the country. 
 
We further suggest that, in building a case for policy 
change to allow charging for blood services, there 
are several considerations.  First, in view of Gerald 
and colleagues10 and the current funding trends at 
NBTS, the user fee should be portrayed as the cost 
of the whole process making the blood safe or what 
we call ‘blood processing fee’ and not the cost of 
blood per se. Secondly, if blood processing fee is 
considered, it can be charged to patients in private 
hospitals whose economic wellbeing is considered 
higher than those in public hospitals, possibly at a 
price higher than the actual blood processing fee.  
However, if safe blood users in public hospitals are to 
be charged, it must be at a price that is much lower 
than the actual blood processing fee. Thirdly, the 
agency needs to institutionalize remedial 
mechanisms to prevent problems associated with 
charging blood processing fee. Foremost, ensuring 
quick access of safe blood to patients needing 
transfusion who have no alternatives in their 
treatment. This is because, patients’ blood 
transfusion need is prescribed by physicians in 
response to acute illness such as severe bleeding and 
thus the service is not demanded electively by the 
patient.15  Similarly, since blood processing fees may 
result in the irrational use of blood because someone 
is paying for it, the agency need to incentivize 
prescribers to not prescribe irrationally. Lastly, since 
there is no direct relationship between the patients 
in the hospital (whether inpatient or blood 
recipients) and NBTS, the revenues from the user 
fees are not guaranteed to flow back to the NBTS. 
As such, instutionalization of user fees means that 
NBTS must rely on an intermediary, the hospital, to 
collect the fees related to transfusion services 15  and 
channel them back to NBTS. Based on negative 
experiences with ‘cost sharing’ collections and 
channeling in other services, it is not guaranteed that 
the hospitals would channel the whole proportion of 
the collected amount. Therefore, the agency needs 
to establish effective financial channeling 
mechanisms from hospitals.  
 
The second cost recovery mechanism is by 
influencing introducing ‘blood services’ within the 
current insurance schemes. Hensher & Jefferys 15 
report that 43-percent of surveyed sub Saharan 
countries substantially funds blood transfusion (BTS) 
services via patient’s charges largely originating 
from health insurance funds. In Tanzania, for 
example, NBTS data suggest that the insurance 
agencies such as; Community Health Funds (CHF), 
National Health Insurance Funds and other private 
insurance agencies have about 12.2-percent of blood 
users, forming a basis for cost-recovery.6,9 However,  
the majority of blood users are under-five children 
(50-percent) and women with pregnancy related 
complications (30-percent), making a total of 80-
percent of the users 6,8,9 who are mostly uninsured 
and are exempted from medical charges. Thus, 
relying on insurance may only result into recovering 
a small percent of the cost of producing safe blood. 
However, compared to other approaches discussed, 
the insurance may be an easier and implementable 
cost-recovery mechanism which requires minimal 
policy changes. 
 
Cost recovery through insurance is part of the 
corporate social responsibility (CSR) in which the 
company embraces the actions to positively impact 
the environment, consumers, employees, 
communities, stakeholders and all other members of 
the public sphere. Although pregnant women, may 
be directly impacted by actions of different 
companies, the majority of blood users (under-five 
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children) are often not directly impacted by 
companies. Furthermore, the majority of the most at 
risk individuals that may require urgent blood 
transfusion for example in Road Traffic Accidents 
e.g. motorcycle or motor vehicle drivers 16 are 
uninsured. Therefore, NBTS must build a strong case 
for companies to ensure they understand the link 
between their business agendas and safe blood 
beneficiaries. This can be achieved by firstly, 
increasing awareness of the need for safe blood 
among insurance members and how safe blood 
contributes to a reduction in deaths compared to 
non-transfusion; as well as how it contributes to a 
reduction in transfusion related diseases and its cost 
effectiveness. Secondly, insisting on the idea of ‘give 
and take’ in which the agency clearly elaborates how 
the insurance companies may in turn benefit under 
CSR, endeavouring a ‘win-win’ situation. In view of 
this, we are suggesting   simple mathematical 
equations that may be used to establish the cost 
effectiveness of blood transfusion services: 
 
 
Table 2 Mathematical Equations used to Establish the Cost Effectiveness of Blood Transfusion Services  
#  of lives saved by blood 
transfusion (number of deaths 
prevented) 
= [# of patients in need of blood transfusion MINUS (# of patients dying after 
transfusion PLUS # of patients who needs but dying without receiving 
transfusion)] 
 
The proportion of HIV infection 
prevented through blood screening 
(HIV Infections if blood was 
transfused without screening) 
= [# of HIV positive blood samples detected through screening  
#  of  blood samples collected (donated)  
 
 
These indicators may be compared across time trajectory (month or years) 
The second indicator can be used also for syphilis, Hepatitis B and C. 
 
Thirdly, establishing friendly mechanisms for cost 
recovery through insurance, for example, a pre-
determined percentage of the total amount of 
insurance claims invoiced by various hospitals in 
other country. This may aim to recover the full or 
partial amount invested by NBTS in collection, 
processing and distribution of safe blood in all 
hospitals country wide. To obtain a percentage of   
operational cost recovery through insurance, we are 
proposing the following formula with the 
assumption that the insurance company meets the 
cost for all patients who received blood transfusion 
regardless of their insurance package through cross 
subsidization:
 
Table 3 Mathematical Equations for Cost Recovery through Insurance 
 
 
 
 
 
 
 
The advantages of this model of payment are 
considered to be;  
 
Desired % recovery 
 
=100 X   [(Total operational cost of units supplied by NBTS to the hospital)  
(Total insurance claims submitted by the hospital)]  
Whereby,  
Total operational cost = [# of units distributed to the hospital x Unit cost (76.18 USD)] 
Total insurance    claims =  The total amount invoiced by the hospital to the insurance agency within a specific   
claim period 
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1.Recovering the amount equivalent to the actual 
units of blood supplied to the hospital by NBTS 
2.Avoiding a flat rate, which may unreasonably 
overburden the hospitals which didn’t receive blood 
within the claim period 
3.Removing over reliance on intermediary hospital to 
collect insurance payments for NBTS as money will 
be deposited directly and on time to the NBTS by 
insurance companies 
1.An incentive for NBTS to collect and distribute 
more blood units;  
2.Reducing administration cost to NBTS  
3.Creating a win-win situation between NBTS and 
insurance companies which may use this as an 
opportunity to increase enrolments of members 
particularly those as risk.  
 
However, there are two considerations for cost 
recovery through insurance. Foremost, if the 
recovered amount comes from the hospitals’ 
insurance claim payments, their buy-in and consent 
for deductions are necessary. This consent may be 
expressed in their contracts with the insurance 
companies which shall channel the agreed 
deductions to NBTS directly, therefore removing the 
need for a hospital as an intermediary. This will then 
be left up to the hospitals to figure out how to 
recover the percentage deducted, risking the 
burdening of the patients if unregulated. The second 
consideration is that, if the equivalent percentage 
comes directly from the insurance company in terms 
of a percentage of their profits generated, likewise, 
buy-in from insurance companies is a prerequisite.   
 
In conclusion, there is a huge demand for safe blood 
in the country, however, the existing ‘external’ 
funding-dependent strategy of collecting blood from 
voluntary non-remunerated blood donors are 
insufficient to meet the need. Therefore, there is a 
need to identify alternative ‘internal’ financial 
mechanisms to sustain the supply of safe blood in the 
country. It is evident that there are several cost 
recovery mechanisms that can be applied in Tanzania 
context, such as blood processing fee (user fee) and 
blood services within insurance schemes. However, in 
each case, policy, ethical and moral issues are the 
major barriers. As such, we recommend a continued 
search for suitable options, however, if the outlined 
strategies are considered for implementation, policy 
change, structural adjustments, massive community 
sensitization and optimum stakeholder engagement 
is warranted to maximize their acceptability within 
the country.  
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